Breaking News

Netherlands Defeats Brazil 3-0 World Cup Consolation Game
Tweet TWEET

NuVasive(R) Management to Participate in Investor Events in May and June 2013

NuVasive(R) Management to Participate in Investor Events in May and June 2013 
SAN DIEGO, CA -- (Marketwired) -- 05/01/13 --  NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
announced today that management will participate in the following
investor events in May and June 2013:  


 
--  Mizuho Securities USA Healthcare Access Day at the Omni Berkshire
    Place in New York City, New York, on Tuesday, May 7, 2013.
    
    
--  BofA Merrill Lynch Healthcare Conference at the Encore at the Wynn
    Resort in Las Vegas, Nevada, on Tuesday, May 14, 2013, at 8:00 a.m.
    PDT.
    
    
--  William Blair 33rd Annual Growth Stock Conference at the Four Seasons
    Hotel in Chicago, Illinois, on Wednesday, June, 12, 2013, at 10:00
    a.m. CDT.
    
    
--  Goldman Sachs 34th Annual Global Healthcare Conference at the Terranea
    Resort in Rancho Palace Verdes, California, on Wednesday, June 12,
    2013, at 10:00 a.m. PDT.

  
Alive webcast of each of the presentations will be available online
from the investor relations page of the Company's corporate website
at www.nuvasive.com. After the live webcast, a replay of the
presentations will remain available on the website for 30 days.  
About NuVasive 
NuVasive is an innovative global medical device company that is
changing spine surgery with minimally disruptive surgical products
and procedurally integrated solutions for the spine. The Company is
the 4th largest player in the $8.2 billion global spine market. 
NuVasive offers a comprehensive spine portfolio of over 80 unique
products developed to improve spine surgery and patient outcomes. The
Company's principal procedural solution is its Maximum Access
Surgery, or MAS(R) platform for lateral spine fusion. MAS provides
safe, reproducible, and clinically proven outcomes, and is a highly
differentiated solution with fully integrated neuromonitoring,
customizable exposure, and a broad offering of application-specific
implants and fixation devices designed to address a variety of
pathologies.  
Having pioneered the lateral approach to spine fusion, NuVasive
continues to be at the forefront of the spine industry's shift toward
less invasi
ve solutions. The Company places a large focus on clinical
research and support of the Society of Lateral Access Surgery, or
SOLAS(R), to expand the body of clinical evidence in support of
NuVasive's minimally disruptive solutions and to drive adoption of
its techniques. The Company's dedication to innovation continues to
spawn game changing technology such as the PCM(R) motion preserving
disc for the cervical spine, XLIF(R) Corpectomy for tumor and trauma,
and Armada(R), which treats adult degenerative scoliosis in a less
invasive fashion. The Company has also developed procedural solutions
that completely redefine and improve upon traditional procedures like
TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are
increasingly being adopted internationally, as the Company lays the
groundwork to continue growing as a global business and to offer
industry-leading, Absolutely Responsive customer service to surgeons
world-wide. NuVasive is focused on becoming a $1 Billion
Start-Up(TM); taking market share by maintaining a commitment to
Superior Clinical Outcomes, Speed of Innovation(R), and Absolute
Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
risk that NuVasive's revenue or earnings projections may turn out to
be inaccurate because of the preliminary nature of the forecasts; the
risk of further adjustment, or unanticipated difficulty in selling
products or generating expected profitability; and other risks and
uncertainties more fully described in NuVasive's press releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange Commission
are available at www.sec.gov. NuVasive assumes no obligation to
update any forward-looking statement to reflect events or
circumstances arising after the date on which it was made. 
Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215
investorrelations@nuvasive.com 
Media Contact:
Nicole Collins
NuVasive, Inc.
858-909-1907
media@nuvasive.com